Federated Hermes’s Seres Therapeutics MCRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-449,086
| Closed | -$21.4M | – | 2132 |
|
|
2023
Q3 | $21.4M | Sell |
449,086
-120,654
| -21% | -$9.21M | 0.06% | 355 |
|
|
2023
Q2 | $54.6M | Sell |
569,740
-194,128
| -25% | -$21.1M | 0.14% | 194 |
|
|
2023
Q1 | $86.6M | Sell |
763,868
-140,429
| -16% | -$15.2M | 0.22% | 96 |
|
|
2022
Q4 | $101M | Sell |
904,297
-20,660
| -2% | -$2.77M | 0.28% | 66 |
|
|
2022
Q3 | $119M | Buy |
924,957
+25,844
| +3% | +$2.65M | 0.35% | 58 |
|
|
2022
Q2 | $61.7M | Buy |
899,113
+498,573
| +124% | +$43M | 0.17% | 160 |
|
|
2022
Q1 | $57M | Buy |
400,540
+54,833
| +16% | +$8.43M | 0.13% | 207 |
|
|
2021
Q4 | $57.6M | Sell |
345,707
-13,398
| -4% | -$2.13M | 0.11% | 246 |
|
|
2021
Q3 | $50M | Buy |
359,105
+241,710
| +206% | +$47.3M | 0.1% | 267 |
|
|
2021
Q2 | $56M | Sell |
117,395
-20,750
| -15% | -$8.76M | 0.1% | 251 |
|
|
2021
Q1 | $56.9M | Sell |
138,145
-9,509
| -6% | -$4.38M | 0.11% | 243 |
|
|
2020
Q4 | $72.3M | Buy |
147,654
+8,171
| +6% | +$4.79M | 0.15% | 176 |
|
|
2020
Q3 | $79M | Buy |
139,483
+88,043
| +171% | +$29.3M | 0.19% | 133 |
|
|
2020
Q2 | $4.9M | Hold |
51,440
| – | – | 0.01% | 716 |
|
|
2020
Q1 | $3.67M | Buy |
51,440
+31,657
| +160% | +$2.12M | 0.01% | 714 |
|
|
2019
Q4 | $1.36M | Sell |
19,783
-873
| -4% | -$64.7K | ﹤0.01% | 1157 |
|
|
2019
Q3 | $1.66M | Buy |
20,656
+20,561
| +21,643% | +$1.36M | ﹤0.01% | 1100 |
|
|
2019
Q2 | $6K | Sell |
95
-50
| -34% | -$4.75K | ﹤0.01% | 1956 |
|
|
2019
Q1 | $20K | Sell |
145
-86,816
| -100% | -$10.6M | ﹤0.01% | 1777 |
|
|
2018
Q4 | $7.86M | Sell |
86,961
-1,552
| -2% | -$217K | 0.02% | 583 |
|
|
2018
Q3 | $13.4M | Buy |
88,513
+21
| +0% | +$3.4K | 0.03% | 471 |
|
|
2018
Q2 | $15.2M | Buy |
88,492
+158
| +0.2% | +$25.8K | 0.04% | 323 |
|
|
2018
Q1 | $13M | Buy |
88,334
+13,511
| +18% | +$2.59M | 0.04% | 352 |
|
|
2017
Q4 | $15.2M | Buy |
74,823
+35,873
| +92% | +$7.37M | 0.04% | 326 |
|
|
2017
Q3 | $12.5M | Buy |
38,950
+1,522
| +4% | +$416K | 0.04% | 360 |
|
|
2017
Q2 | $8.46M | Sell |
37,428
-2,446
| -6% | -$502K | 0.02% | 437 |
|
|
2017
Q1 | $8.99M | Sell |
39,874
-15,762
| -28% | -$3.2M | 0.03% | 436 |
|
|
2016
Q4 | $11M | Sell |
55,636
-46,543
| -46% | -$10.2M | 0.03% | 390 |
|
|
2016
Q3 | $25.1M | Buy |
102,179
+2,632
| +3% | +$923K | 0.07% | 222 |
|
|
2016
Q2 | $57.8M | Buy |
99,547
+47,630
| +92% | +$27.9M | 0.17% | 103 |
|
|
2016
Q1 | $27.6M | Buy |
51,917
+17,168
| +49% | +$8.96M | 0.09% | 202 |
|
|
2015
Q4 | $24.4M | Buy |
34,749
+6,149
| +22% | +$4.04M | 0.08% | 243 |
|
|
2015
Q3 | $17M | Buy |
+28,600
| New | +$23.3M | 0.05% | 319 |
|
Other funds holding MCRB
FP
Federated Hermes's MCRB Position: Q4 2023 in Review
Federated Hermes sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 449,086 shares — an estimated $21.4M sold.
Federated Hermes first reported a position in MCRB in Q3 2015 and held it in 33 quarters. The position peaked at $119M in Q3 2022. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.
- Federated Hermes reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
- Federated Hermes sold 449,086 Seres Therapeutics shares in Q4 2023, an estimated $21.4M.
- Federated Hermes first reported a position in Seres Therapeutics in Q3 2015 and held it in 33 quarters.
- Federated Hermes's Seres Therapeutics position peaked at $119M in Q3 2022.
- 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.
Based on Federated Hermes's 13F filing for Q4 2023, filed 31 Jan 2024.